ORLANDO, Fla.--(BUSINESS WIRE)--MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT) specializing in the development, manufacturing, and marketing of immuno-assays and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces an investment by UNIC Medical, Inc.'s Chairman and UNIC Technologies, Inc.’s CEO, Dr. Zhongxi Zheng, an MD in Pathology. His investment represents 5.06% of MEDITE’s outstanding common shares after the investment. In exc
| < Prev | Next > |
|---|
